Company / Cash & Equivalents
Silence Therapeutics plc Cash & Equivalents History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$11.3M
FY2025
5-year range
$11.3M / $121.3M
FY2024-FY2025
Trend
-90.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$11M in FY2025.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, cash & equivalents decreased 90.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -22.49 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.3M | -90.7% |
| FY2024 | $121.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026